3 Top Growth Plays That Could Smash The FTSE 100: ARM Holdings plc, GlaxoSmithKline plc & Diageo plc

Though the FTSE 100 (INDEXFTSE:UKX) could go much higher, ARM Holdings plc (LON:ARM), GlaxoSmithKline plc (LON:GSK) & Diageo plc (LON:DGE) could beat it.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE100

With the S&P 500 hitting record highs, 2014 has been something of a disappointment for the FTSE 100. Indeed, the index is up just 1% since the turn of the year, but does seem to have huge potential over the medium term. That’s because it trades on a price to earnings (P/E) ratio of just 13.8 and has a yield of around 3.5% — both of which indicate that the index could push northwards.

However, here are three shares that despite the FTSE 100’s potential, could still outperform the UK’s main index.

ARM

Although shares in ARM (LSE: ARM) have fallen by 12% during the course of 2014, the intellectual property business could beat the FTSE 100 going forward. That’s because it offers investors a vast amount of growth potential, with the company’s earnings per share (EPS) expected to increase by an impressive 23% in 2015. Furthermore, with shares in ARM having fallen, they now represent much better value for money. Indeed, although ARM’s price to earnings (P/E) ratio remains high at 41.5, its price to earnings growth (PEG) ratio of just 1.5 means that it could outperform the FTSE 100 over the medium term.

GlaxoSmithKline

As with ARM, 2014 has been a tough year for GlaxoSmithKline (LSE: GSK). Its shares have dropped by 9% and the company continues to suffer from weak sentiment due to bribery allegations. However, GlaxoSmithKline also has a highly diversified and capable drugs pipeline that has the potential to deliver brisk earnings growth in future years. Certainly, all drug pipelines come with a large dollop of uncertainty, but GlaxoSmithKline appears to have a well-balanced pipeline that should benefit from a renewed focus by the company after the sale of its consumer brands. In the meantime, a yield of 5.6% should help to push investors’ total return above that of the FTSE 100.

Diageo

Diageo (LSE: DGE) is also down in 2014, with the alcoholic beverages company seeing its share price fall by 12% year-to-date. However, demand for premium alcoholic drinks should remain robust in the long run – even if the world economy does fall back into negative growth territory. Moreover, Diageo’s strong stable of brands should ensure that demand for its products remains buoyant in developed nations, while emerging markets such as China and India present a huge opportunity for the company to increase its sales and profitability. As a result, it could have a much brighter future and has the scope to beat the main index moving forward.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended shares in GlaxoSmithKline and ARM Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Red lorry on M1 motorway in motion near London
Investing Articles

Are we looking at a once-in-a-decade chance to buy cut-price FTSE 100 shares?

Harvey Jones says lots of FTSE 100 shares are trading near 10-year lows, presenting a terrific buying opportunity for brave…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

£5,000 invested in Nvidia stock 6 months ago is now worth…

Nvidia stock's taking a breather at the moment. But it could be getting ready for its next move higher, says…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

I hold Lloyds. Is it madness to buy Barclays shares too?

Harvey Jones is keen to buy Barclays shares but wonders whether he's simply doubling down, given that he already holds…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

It’s time we all took a long, cold look at the Lloyds share price

The Lloyds share price has been good to Harvey Jones, making him a huge fan of the FTSE 100 bank.…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Warren Buffett didn’t retire early. But could his investing wisdom help you do so?

Warren Buffett's wisdom from decades of stock market investing is actionable even for a modest investor who simply aims to…

Read more »

Young female hand showing five fingers.
Investing Articles

5 compelling investment ideas for a Stocks and Shares ISA in 2026

Edward Sheldon discusses some ideas to consider for a Stocks and Shares ISA and highlights a UK stock that could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Is this the best time to buy shares in a long time?

Earlier this week, Bill Ackman stated on X that this is the best time to buy shares in a long…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

£1,000 buys 35 shares in an incredibly reliable FTSE 100 dividend stock

Despite falling 72% from their highs, shares in this FTSE 100 company have been an incredibly reliable source of dividend…

Read more »